425: Sonnet BioTherapeutics Pivots to Cryptocurrency Treasury Strategy via $888 Million Business Combination with Rorschach I LLC

Sonnet BioTherapeutics Holdings, Inc. announced a definitive agreement for a business combination with Rorschach I LLC, a newly-formed entity affiliated with Atlas Merchant Capital LLC and Paradigm Operations LP, to transform into Hyperliquid Strategies Inc. (HSI), a publicly listed cryptocurrency treasury company focused on HYPE tokens.

Summary

• Sonnet BioTherapeutics Holdings, Inc. (Sonnet) has entered into a Business Combination Agreement (BCA) with Rorschach I LLC (Rorschach), Hyperliquid Strategies Inc. (Pubco/HSI), TBS Merger Sub Inc., and Rorschach Merger Sub LLC.
• The transaction involves Rorschach Merger Sub merging into Rorschach, and Company Merger Sub merging into Sonnet, with both surviving as wholly-owned subsidiaries of Pubco (HSI).
• The Mergers are expected to be completed in the second half of 2025.
• At closing, Pubco (HSI) is expected to hold approximately $583 million in HYPE tokens (based on an agreed spot price of $46.372 per HYPE token) and have at least $305 million in cash on its balance sheet, totaling an assumed closing value of $888 million.
• Existing Sonnet equityholders (excluding PIPE investors) will receive one share of Pubco Common Stock and one contractual contingent value right (CVR) for each share of Sonnet Common Stock.
• The CVR represents the right to receive Pubco Common Stock based on net proceeds from the sale, license, or disposition of Sonnet's 'Legacy Assets' (drug development programs like SON-1010, SON-1210, SON-1400, SON-1411, SON-080) within three years post-closing. There is no assurance CVR holders will receive any shares.
• Current Sonnet equityholders (including initial PIPE investors) are anticipated to own approximately 1.2% of outstanding Pubco Common Stock post-closing, while Rorschach equityholders and subscribers will own approximately 98.8%.
• Sonnet will raise an aggregate $5.5 million in a private placement of Series 5 Convertible Preferred Stock and warrants, expected to close on July 14, 2025. Additionally, $2.0 million in convertible notes from June 2025 will convert into Series 5 Preferred Stock and warrants.
• Net proceeds from these raises will be used by Sonnet for general corporate purposes and working capital requirements, including the continued development of its biotech assets for future sale.
• Pubco will issue shares equal to 5% of fully-diluted outstanding Pubco Common Stock and warrants to purchase 15% of fully-diluted outstanding Pubco Common Stock to Rorschach Advisors LLC (the Advisor). These Advisor Warrants have exercise prices of $1.875, $2.50, and $3.75.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the significant capital infusion, strategic pivot into a high-growth (albeit volatile) sector with prominent investors, and the potential for legacy asset monetization. However, the inherent volatility and regulatory uncertainty of cryptocurrency, coupled with the substantial dilution for existing shareholders, temper the overall positive outlook.

Positives

• Significant capital infusion: The combined entity is expected to hold approximately $583 million in HYPE tokens and at least $305 million in cash, totaling an assumed closing value of $888 million.
• Strategic pivot to a cryptocurrency treasury company (Hyperliquid Strategies Inc.) with a focus on HYPE tokens, positioning it as a potentially leading player in the digital asset space.
• Involvement of prominent strategic investors: Paradigm, Galaxy Digital, Pantera Capital, D1 Capital, Republic Digital, and 683 Capital.
• New experienced leadership: Bob Diamond (Co-founder and CEO of Atlas) will be named Chairman of the Board, David Schamis (CIO and Co-founder of Atlas) will be named Chief Executive Officer of HSI, and Eric Rosengren (former Boston Fed President) will join the board.
• Potential for existing biotech assets to be monetized through Contingent Value Rights (CVRs), providing a potential future payout to legacy shareholders.
• Continued listing on the Nasdaq Capital Market under a new ticker symbol.

Negatives

• Significant dilution for existing Sonnet shareholders, who will own only approximately 1.2% of the combined entity (HSI) post-closing.
• The Contingent Value Rights (CVRs) for legacy biotech assets are highly speculative, with no assurance of payment, and are non-transferable except in limited circumstances.
• The new business strategy is centered on a highly volatile asset (HYPE token), introducing substantial market risk.
• The company will be subject to enhanced regulatory oversight due to its cryptocurrency treasury strategy, with significant legal and regulatory uncertainties surrounding digital assets.
• Potential for impairment charges if the fair value of HYPE decreases, leading to volatility in reported earnings.
• Risk of becoming subject to the corporate alternative minimum tax (CAMT) under the Inflation Reduction Act of 2022 due to fair value accounting of HYPE holdings.
• Reliance on unregulated HYPE trading venues, which may experience fraud, security failures, or operational problems.
• Concentration of assets in HYPE tokens limits diversification and enhances risk.
• HYPE holdings are less liquid than cash and cash equivalents, potentially limiting liquidity for working capital needs.

Risks

• Completion of the Mergers is subject to a number of conditions, including stockholder approval and regulatory clearances, which may not be satisfied or completed on a timely basis or at all, potentially resulting in significant costs and loss of benefits.
• HYPE is a highly volatile asset, and fluctuations in its price may adversely influence financial results and the market price of listed securities due to factors like decreased user confidence, large holder dispositions, negative publicity, competition from other blockchains/digital assets, and network developments.
• HYPE and other digital assets are subject to significant legal and regulatory uncertainty, with evolving interpretations of securities laws and potential for new laws or enforcement actions that could materially impact HYPE's price or the ability to own/transfer it.
• The cryptocurrency treasury strategy subjects the company to enhanced regulatory oversight, including anti-money laundering and sanctions laws, and potential restrictions if HYPE is acquired from 'bad actors'.
• There is a risk that HYPE may be classified as a security by regulators or courts, which would subject the company to additional regulation and could make it impractical to continue segments of the business as currently contemplated, potentially requiring registration as an investment company.
• The company plans to use a portion of its capital to acquire HYPE, which may adversely affect financial results and stock price due to HYPE's volatility and potential impairment charges under ASU 2023-08.
• Unrealized fair value gains on HYPE holdings could cause the company to become subject to the 15% corporate alternative minimum tax (CAMT) under the Inflation Reduction Act of 2022, potentially resulting in a material cash tax obligation.
• The unregulated nature and lack of transparency of many HYPE trading venues may lead to greater fraud, security failures, or operational problems, adversely affecting HYPE's value and investor confidence.
• The concentration of HYPE holdings limits risk mitigation and enhances the impact of any significant declines in HYPE price on the company's financial condition.
• The emergence or growth of other blockchains and associated digital assets could negatively impact the price of HYPE.
• HYPE holdings will be less liquid than cash and cash equivalents, potentially limiting their ability to serve as a source of liquidity, especially during market instability.

Future Outlook

The combined entity, Hyperliquid Strategies Inc. (HSI), will pivot its core business to building a strategic reserve of HYPE, the native token of the Hyperliquid Layer-1 blockchain, aiming to become a leading publicly listed cryptocurrency treasury company. The substantial cash proceeds from the transaction are expected to enable HSI to acquire significantly more HYPE tokens. Sonnet's existing oncology-focused biotechnology assets, including SON-1010, will continue to be developed and are targeted for future monetization, with potential contingent value right (CVR) payments to legacy shareholders.

Management Comments

• Bob Diamond, Co-founder and CEO of Atlas: "We are delighted by this opportunity to partner with Sonnet in establishing a leading crypto treasury management strategy to ultimately deliver strong value to shareholders. We believe HYPE and the Hyperliquid protocol represent a truly differentiated offering within the digital asset space. We believe Hyperliquid Strategies will be well placed to maximize these opportunities because of our unique team of investors and operators with deep, relevant crypto and financial services experience."
• Matt Huang, Co-founder of Paradigm: "Hyperliquid has broken out as a crypto project with real fundamentals: strong core contributors, exacting product quality, and meteoric growth. We hear lots of institutional demand for exposure to Hyperliquid, yet the native token HYPE is difficult to access in the United States. We are excited about this treasury strategy, which we believe will contribute to the Hyperliquid ecosystem in many ways over time."
• Raghu Rao, Sonnet's Interim Chief Executive Officer: "Following a thorough review, we believe this proposed combination with Rorschach provides us with a unique and exciting opportunity. We will be able to capitalize on the recent advancements around digital assets and equip Sonnet with funding to potentially realize the future value of our existing biotech assets. We believe this transaction and the strategic options it provides offer Sonnet and our shareholders with an innovative path forward and the potential for significant value creation."
• Nailesh Bhatt, Chairman of the Board of Directors of Sonnet: "On behalf of the Sonnet Board, we are incredibly grateful to Raghu for stepping in as interim CEO and spearheading the operational and strategic efforts despite the turbulent times. We believe this transaction holds a lot of promise and opportunity, and we are dedicatedly working to bring it to fruition. Raghu along with the rest of the leadership at Sonnet attributed significant efforts into determining the best path forward and we believe this transaction clearly represents just that. We are excited for the next phase ahead and look forward to optimizing value for all stakeholders."

Industry Context

This announcement signifies a dramatic strategic pivot for Sonnet BioTherapeutics from a traditional oncology-focused biotechnology company to a cryptocurrency treasury company. This move aligns with a broader trend of companies exploring digital assets for treasury management and investment, particularly in the context of the growing Layer-1 blockchain ecosystem. The involvement of prominent crypto investment firms like Paradigm and Galaxy Digital suggests a validation of the Hyperliquid protocol and HYPE token within the digital asset industry. The transaction aims to address the difficulty of accessing HYPE tokens in the U.S. institutional market, potentially creating a new avenue for institutional exposure to this specific digital asset.

Comparison to Industry Standards

• The document highlights Hyperliquid as a 'layer one (L1) blockchain engineered for transparent high-frequency decentralized transactions' and notes HYPE as the '11th-largest cryptocurrency by market capitalization' as of July 2025, according to Forbes.
• It mentions Hyperliquid's proof-of-stake mechanism in contrast to Ethereum's transition to a similar mechanism, implying a competitive landscape among L1 blockchains.
• The transaction aims to create 'one of the top strategic reserves of the HYPE token,' suggesting a goal to be a leading holder in this specific digital asset market segment.

Management Changes

Corporate Governance

Legal Proceedings

• The document highlights significant legal and regulatory uncertainty in the digital asset industry, citing past SEC actions against various crypto entities (e.g., BlockFi, Uniswap Labs, OpenSea, Binance, Kraken, Coinbase) and a civil enforcement action by the State of Oregon against Coinbase.
• It notes that while some complaints were dismissed, the SEC or other regulatory agencies may initiate similar actions in the future, which could materially impact the operations or functionality of Hyperliquid, the price of HYPE, and the company's ability to own or transfer HYPE.
• The company acknowledges the risk of enforcement proceedings and lawsuits if HYPE is determined by a regulatory body or court to be a security or to be bought and sold in securities transactions.

Related Party Transactions

• Rorschach I LLC is a newly-formed entity affiliated with Atlas Merchant Capital LLC and Paradigm Operations LP, which are key sponsors of the business combination.
• Rorschach Advisors LLC (the Advisor), a Delaware limited liability company, will receive Pubco Common Stock equal to 5% of the fully-diluted outstanding shares and warrants to purchase 15% of the fully-diluted outstanding shares of Pubco Common Stock.
• Pubco and the Advisor will enter into an Advisor Rights Agreement, granting the Advisor director nomination rights and information rights.
• Pubco and the Advisor will enter into a Strategic Advisor Agreement, under which the Advisor will provide technical advisory services related to the digital asset ecosystem, Hyperliquid, and strategic advice regarding digital assets treasury operations for five years.
• David Schamis, CIO and Co-founder of Atlas Merchant Capital, will be named Chief Executive Officer of HSI.
• Robert Diamond, Co-founder and CEO of Atlas Merchant Capital, will be named Chairman of the Board of HSI.
• Two current Sonnet board members, Nailesh Bhatt and Albert Dyrness, will remain on the Pubco board.
• Chardan Capital Markets, LLC acted as the exclusive advisor to Sonnet and Rorschach with respect to the Closing PIPE and is entitled to receive a fee of 7.0% of the aggregate gross proceeds raised, plus expense reimbursement up to $100,000 if the Closing occurs.

Stakeholder Impact

• **Shareholders (Legacy Sonnet)**: Will experience significant dilution, owning approximately 1.2% of the combined entity. They will receive Contingent Value Rights (CVRs) for potential future monetization of Sonnet's legacy biotech assets, but these are highly speculative and non-transferable.
• **Shareholders (New HSI Investors)**: Will gain significant ownership (approximately 98.8%) in a new public company focused on cryptocurrency treasury management, providing exposure to the HYPE token and the Hyperliquid ecosystem.
• **Employees (Sonnet)**: Raghu Rao will remain CEO of Sonnet as a wholly-owned subsidiary, indicating continuity for the biotech operations. Key officers received RSU grants, aligning their interests with the transaction's success.
• **Management (New HSI)**: A new leadership team from Atlas Merchant Capital will take over the combined entity, bringing expertise in financial services and digital assets.
• **Customers/Partners (Sonnet Biotech)**: Sonnet will continue focusing on existing biotech assets and commercial partnering discussions, suggesting ongoing operations and potential for future development and monetization of these assets.
• **Creditors**: The significant capital raise and new treasury strategy could impact the company's financial health and ability to meet obligations, though the document highlights substantial cash on the balance sheet post-closing.

Next Steps

• Completion of Mergers is expected in the second half of 2025.
• Sonnet will seek stockholder approval for the Business Combination Agreement and the transactions contemplated thereby.
• Pubco will prepare and file a registration statement on Form S-4 with the SEC to register the shares of Pubco Common Stock to be issued in connection with the Mergers.
• Pubco will enter into an Advisor Rights Agreement and a Strategic Advisor Agreement with Rorschach Advisors LLC.
• Pubco will enter into a Contingent Value Rights Agreement with a rights agent.
• Pubco will enter into a Registration Rights Agreement with the Advisor and certain investors in Rorschach.
• Pubco will distribute a joint press release announcing the consummation of the transactions concurrently with the Closing.
• Pubco will file a Current Report on Form 8-K with the SEC within four business days after the Closing.
• Sonnet will continue focusing on existing biotech assets, including the development of SON-1010, while disposing of other assets.
• Sonnet will continue to engage in commercial partnering discussions focused on its biotech assets.
• If needed, the Company will hold a meeting of its stockholders for the approval of an increase in the number of authorized shares of Common Stock.

Key Dates

Recommendation

Keywords

Cryptocurrency, HYPE token, Hyperliquid, Business Combination, Merger, Digital assets, Treasury management, Biotechnology, Oncology, SEC filing, Financial reporting, Corporate governance, Risk management, Strategic analysis, NASDAQ, SONN, Atlas Merchant Capital, Paradigm, Contingent Value Rights, PIPE financing